ArticleNature immunology2023
Exhausted intratumoral Vδ2
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 73 citations in OpenAlex.
- Article
- Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells.Journal of translational medicine · 2026Article
- Article
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Single-cell landscape of human liver sinusoidal γδ T cells in the context of latent human cytomegalovirus infection.Nature communications · 2026Article
- Unconventional T cells in urological cancers: catch them if you can.Nature reviews. Urology · 2026Review
- Review
- Effector Vδ1 γδ T cells mediate anti-tumor immunity and are reprogrammed by imatinib in human gastrointestinal stromal tumor.Research square · 2026Article
- Harnessing Self-Assembling Peptides on γδ T Cells to Enhance Anti-Tumor Immunity.Polymer science & technology (Washington, D.C.) · 2026Article
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?Journal for immunotherapy of cancer · 2026Article
- Article
- γδ T cells at the interface of innate and adaptive immunity in cancer.Journal for immunotherapy of cancer · 2026Review
- Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia.Cancers · 2026Article
- Follow the "DOTs": Vδ1+ γδ T cells as effectors of cancer immunotherapy.The Journal of experimental medicine · 2026Review
- Fitness Training for γδ T cells in mouse and human atherosclerosis takes place in plaques and artery tertiary lymphoid organs.Genome medicine · 2026Article
- Single-cell profiling reveals diverse γδ T cell subsets in ulcerative colitis.Science immunology · 2026Article
- Functionally heterogeneous intratumoral CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Immune checkpoint TIM-3 in tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
Gamma delta (γδ) T cells reside within human tissues including tumors, but their function in mediating antitumor responses to immune checkpoint inhibition is unknown. Here we show that kidney cancers are infiltrated by Vδ2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.